Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Indoco Remedies Ltd
Cost of Revenue
Indoco Remedies Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indoco Remedies Ltd
NSE:INDOCO
|
Cost of Revenue
-₹5.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-6%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹118.8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-16%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹94.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹113.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cost of Revenue
-₹71.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹31B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
See Also
What is Indoco Remedies Ltd's Cost of Revenue?
Cost of Revenue
-5.6B
INR
Based on the financial report for Mar 31, 2025, Indoco Remedies Ltd's Cost of Revenue amounts to -5.6B INR.
What is Indoco Remedies Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-6%
Over the last year, the Cost of Revenue growth was 12%. The average annual Cost of Revenue growth rates for Indoco Remedies Ltd have been -3% over the past three years , -8% over the past five years , and -6% over the past ten years .
